A SPAC I Acquisition Corp.
ASCAU
NASDAQ Capital Market2.96
USD
-7.94
- -
CIK
0001868775
ISIN
VGG0542S1222
CUSIP
G0542S122
Return %
Stock
S&P500
1Y
-73.09
26.53
3Y
-70.52
76.60
5Y
-70.52
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Sze Wai Tsang CFA
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- Marina Bay Financial Centre Singapore Singapore 018983
- IPO Date
- Feb 15, 2022
- CIK
- 0001868775
- Similar Companies
- Business
- A SPAC I Acquisition Corp. (ASCAU) operates as a blank check company whose principal business activity is to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company targets opportunities primarily in the technology, media, telecom, and e-commerce sectors in the United States and Asia, excluding China; it holds no significant operations prior to completing such a transaction. Incorporated in 2021 and headquartered in Singapore, A SPAC I Acquisition Corp. raised approximately $69 million in its initial public offering on February 15, 2022, with units comprising one Class A ordinary share, three-quarters of a redeemable warrant exercisable at $11.50 per share, and one right convertible to one-tenth of a share. In its most significant development, the company completed a business combination with NewGenIvf Limited on April 3, 2024, following shareholder approval on March 4, 2024, and multiple charter extensions including on October 9, 2023; the transaction valued NewGenIvf at a $50 million enterprise value, with the combined entity renamed NewGenIvf Group Limited and relisted on Nasdaq under the tickers NIVF and NIVFW. Post-merger, ASCAU units continue to trade separately, reflecting residual activity from the de-SPAC process, though the core SPAC structure has transitioned to the healthcare-focused fertility services provider operating in Asia.